SpringerPlus

Table 1 Characteristics of patients treated with FEC100-taxotere and FEC100-taxotere-herceptin

From: ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors

	FEC100-taxotere		FEC100-taxotere-herceptin
	N = 118	%^a	N = 46	%^a
Tumor type
Ductal carcinoma	106	89.9	44	95.6
Lobular carcinoma	7	5.9	1	2.2
Other	5	4.2	1	2.2
Tumor size
T0-T1	5	4.3	1	2.3
T2	60	51.7	21	48.8
T3	24	20.7	11	25.6
T4	27	23.3	10	23.3
NA	2	1.7	3	6.5
Histoprognostic grade
SBRI	7	6.7	1	2.5
SBRII	54	51.9	19	47.5
SBRIII	43	41.3	20	50
NA	14	11.9	6	13.1
Nodal status
Positive	63	54.3	30	65.2
Negative	53	45.7	16	34.8
NA	2	1.7	0	0
Hormone receptor status
Positive^b	77	66.3	23	50.0
Negative^c	39	33.6	23	50.0
NA	2	1.7	0	0.0
HER-2 status
Positive^d	5	4.7	46	100.0
Negative	102	95.3	0	0.0
NA	11	9.3	0	0.0
Clinical response
CR	11	12.2	7	21.9
PR	62	68.9	23	71.9
SD	15	16.7	2	6.3
PD	2	2.2	0	0.0
NA	28	23.7	14	30.4
pCR
Yes	25	21.2	18	40.0
No	93	78.8	27	60.0
NA	0	0.0	1	2.2

CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not applicable, pCR pathological complete response.
^aPercentages of evaluable patients (except for NA: percentage of all patients).
^bEstrogen receptor or progesterone receptor positive.
^cEstrogen receptor and progesterone receptor negative.
^dIHC3+ or IHC2+/FISH+ or CISH+.

Back to article page